A
Avenge Bio
Focusing cell generated immunotherapies to eradicate solid tumors
About Avenge Bio
Avenge Bio is a biotech startup that focuses on developing innovative therapeutics to combat solid tumors. The company's primary product is its proprietary LOCOcyteTM platform, which is designed to deliver cytokines and other immunomodulatory molecules in a controlled manner. This approach aims to stimulate strong local and systemic anti-tumor immune responses, without the side effects associated with traditional immunotherapies.
The company's target market includes patients suffering from hard-to-treat solid tumors. Avenge Bio's business model revolves around the research, development, and commercialization of its LOCOcyteTM platform. The company generates revenue through the sales of its therapeutics and through partnerships with other healthcare entities.
One of the company's ongoing projects is a Phase 1/2 study of AVB-001, a treatment for patients with serous adenocarcinoma of the ovary. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2), a type of protein that regulates the activities of white blood cells that are responsible for immunity. The product is delivered directly into the peritoneal cavity, the space within the abdomen that contains the intestines, stomach, and liver.
Avenge Bio was founded by a team of experienced biotech executives, including CEO Michael Heffernan, a seasoned biopharmaceutical entrepreneur with over three decades of experience. The company's work is backed by leading healthcare investors such as Longitude Capital, CAM Capital, Perceptive Xontogeny, and Rock Springs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Natick, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 75.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $45M | $180M | Pappas Capital · Longitude Capital · Perceptive Advisors · CAM Capital | ↗ |
| OtherOther financing | Mar 2020 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Avenge Bio is 1.1K monthly website visits, up 292.9% over the last three months. Avenge Bio's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Perceptive Advisors
CAM Capital
Pappas Capital
Longitude Capital
Palico
Rock Springs Capital
Other known investors2 additional known investors
Rice University
Xontogeny
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avenge Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avenge Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.